Johnson & Johnson vs Arcus Biosciences, Inc. — Stock Comparison
Johnson & Johnson (JNJ) and Arcus Biosciences, Inc. (RCUS) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson clearly outscores Arcus Biosciences, Inc. on Q·Score (7.1 vs 5.1 out of 10), led by Quality (9.3 vs 0.2) and Valuation (7.3 vs 6). Arcus Biosciences, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for RCUS (+47.1%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-156% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs RCUS: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Arcus Biosciences, Inc. (RCUS) at 5.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or RCUS?
Johnson & Johnson (JNJ) scores higher on Growth (5.1/10 vs 4.5/10). Johnson & Johnson reports revenue growth (9.9% YoY) while Arcus Biosciences, Inc. reports (-39.3% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or RCUS more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 6/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs RCUS?
There are 23 analysts covering JNJ with a consensus price target of $252.87, and 12 analysts covering RCUS with a consensus target of $35.75. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or RCUS?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 0.2/10). Net profit margin: JNJ at 21.8%, RCUS at -156.4%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or RCUS?
Arcus Biosciences, Inc. (RCUS) scores higher on Financial Health (9.2/10 vs 6.5/10). Market beta: JNJ at 0.26, RCUS at 0.84. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and RCUS?
Johnson & Johnson (JNJ) has a market capitalisation of $549.8B, while Arcus Biosciences, Inc. (RCUS) has a market cap of $3.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →